A new study out Thursday shows remdesivir, the only antiviral therapeutic approved for treatment of the novel Wuhan coronavirus, does not prevent deaths in COVID-19-infected patients.
The study, conducted by the World Health Organization (WHO) tracked more than 11,300 adults across 30 different countries to examine the mortality rate benefits of the drug manufactured by Gilead. President Donald Trump was administered the medicine following symptoms related to his infection with the virus.
According to researchers in a paper that has not yet been peer-reviewed, remdesivir, hydroxychloroquine, lopinavir, and interferon drugs, when administered either separately or in a combination, “appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.”
Remdesivir was given emergency authorization by the Food and Drug Administration in May after a study from the National Institutes of Health found the drug produced modest benefits in coronavirus-stricken patients. The National Institutes of Health also includes